Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
Daniel Edmonston(Duke University), Neha J. Pagidipati(Duke University), Hillary Mulder(Clinical Research Institute), Christina M. Shay, Kelly J. Hunt(Medical University of South Carolina), Wenke Hwang(Penn State Milton S. Hershey Medical Center), Keith Marsolo(University of Cincinnati), Raj C. Shah, Javed Butler(Jackson Memorial Hospital), Hayden B. Bosworth(Durham VA Health Care System), W Schuyler Jones(Duke University), Alex R. Chang, Vivian Fonseca(Tulane University), Faraz S. Ahmad(Northwestern University), Ajaykumar Rao(Temple University), Alanna M. Chamberlain(WinnMed), Adriana M. Hung(Nashville Oncology Associates), Elizabeth Lydon(Duke University), Daniel E. Ford(Johns Hopkins University), Isabelle Ayoub(The Ohio State University Wexner Medical Center), Zachary Lampron(Duke University), Howard S. Gordon(University of Illinois Chicago), Karen Chiswell(Amyloidosis Foundation)
Cited by 31
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Heart Disease and Stroke Statistics—2021 Update
|Circulation|2021|5.7k